HighTower Trust’s Exagen XGN Stock Holding History

HighTower Trust’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,683,578	Closed	-$231K	–	328
2022 Q2	$231K	Buy	+2,683,578	New	+$15.6M	24.22%	1

Other funds holding XGN

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

HighTower Trust's XGN Position: Q3 2022 in Review

HighTower Trust sold out of Exagen (XGN) in Q3 2022, closing a stake of 2,683,578 shares — an estimated $231K sold.

HighTower Trust first reported a position in XGN in Q2 2022 and held it in 1 quarter. The position peaked at $231K in Q2 2022. 38 funds tracked by Wall St. Rank hold XGN as of Q3 2022.

HighTower Trust reported no remaining Exagen position as of Q3 2022 after selling out during the quarter.
HighTower Trust sold 2,683,578 Exagen shares in Q3 2022, an estimated $231K.
HighTower Trust first reported a position in Exagen in Q2 2022 and held it in 1 quarter.
HighTower Trust's Exagen position peaked at $231K in Q2 2022.
38 funds tracked by Wall St. Rank held Exagen as of Q3 2022.

Based on HighTower Trust's 13F filing for Q3 2022, filed 7 Oct 2022.